Our in vivo study also showed that metformin could decrease the expression levels of cyclin D1 in a bladder cancer xenograft model and suggests that metformin may be a valuable potential therapeutic agent to block bladder tumor growth. Here, CCND1 is linked to urinary bladder carcinoma.